

1 **Title Page:**

2 **Reverse transcription loop-mediated isothermal amplification combined with**
3 **nanoparticles-based biosensor for diagnosis of COVID-19**

4

5 Xiong Zhu ^{1,*}, Xiaoxia Wang ^{1,*}, Limei Han ¹, Ting Chen¹, Licheng Wang ¹, Huan Li ¹,
6 Sha Li ¹, Lvfen He ¹, Xiaoying Fu ¹, Shaojin Chen ¹, Mei Xing ⁴, Hai Chen ¹ and Yi
7 Wang ^{2,3,†}

8 ¹ Central & Clinical Laboratory of Sanya People's Hospital, Sanya, Hainan 572000,
9 People's Republic of China.

10 ² Department of Respiratory Disease, Beijing Pediatric Research Institute, Beijing
11 Children's Hospital, Capital Medical University, National Center for Children's
12 Health, Beijing 10045, P. R. China.

13 ³ Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Key
14 Laboratory of Pediatric Respiratory Infection Disease, National Clinical Research
15 Center for Respiratory Diseases, Beijing Children's Hospital, Capital Medical
16 University, National Center for Children's Health, Beijing 10045, P. R. China.

17 ⁴ Wenchang People's Hospital, Sanya, Hainan 572000, P. R. China.

18 **Short title:** COVID-19 RT-LAMP-NBS assay

19 **Figure:** 6

20 **Tables:** 0

21 **Supplementary Materials:** 1

22 † Correspondence: **Yi Wang**

23 Department of Respiratory Infection Disease, Beijing Pediatric Research Institute,
24 Beijing Children's Hospital, National Center for Children's Health, No. 56, Nanlishi
25 Road, Xicheng District, Beijing 100045, China.

26 E-mail: wildwolf0101@163.com

27

28 *These authors contributed equally to this article

29 **ABSTRACT**

30 Given the scale and rapid spread of severe acute respiratory syndrome coronavirus 2
31 (SARS-CoV-2, known as 2019-nCov) infection (COVID-19), the ongoing global
32 SARS-CoV-2 outbreak has become a huge public health issue. Rapid and precise
33 diagnostic methods are thus immediately needed for diagnosing COVID-19,
34 providing timely treatment and facilitating infection control. A one-step reverse
35 transcription loop-mediated isothermal amplification (RT-LAMP) coupled with
36 nanoparticles-based biosensor (NBS) assay (RT-LAMP-NBS) was successfully
37 established for rapidly and accurately diagnosing COVID-19. A simple equipment
38 (such as heating block) was required for maintaining a constant temperature (63°C)
39 for only 40 min. Using two designed LAMP primer sets, F1ab (opening reading frame
40 1a/b) and np (nucleoprotein) genes of SARS-CoV-2 were simultaneously amplified
41 and detected in a 'one-step' and 'single-tube' reaction, and the detection results were
42 easily interpreted by NBS. The sensitivity of SARS-CoV-2 RT-LAMP-NBS was 12
43 copies (each of detection target) per reaction, and no cross-reactivity was generated
44 from non-SARS-CoV-2 templates. Among clinically diagnosed COVID-19 patients,
45 the analytical sensitivity of SARS-CoV-2 was 100% (33/33) in the oropharynx swab
46 samples, and the assay's specificity was also 100% (96/96) when analyzed the clinical
47 samples collected from non-COVID-19 patients. The total diagnosis test from sample
48 collection to result interpretation only takes approximately 1 h. In sum, the
49 RT-LAMP-NBS is a promising tool for diagnosing the current SARS-CoV-2
50 infection in first line field, public health and clinical laboratories, especially for
51 resource-challenged regions.

52 **KEYWORDS:** SARS-CoV-2; COVID-19; Rapid diagnosis; Reverse transcription
53 loop-mediated isothermal amplification; Biosensor.

54 INTRODUCTION

55 In late December 2019, an unexpected outbreak caused by severe acute respiratory
56 syndrome coronavirus 2 (SARS-CoV-2, known as 2019-nCov) emerged in Wuhan,
57 Hubei province, China, which had previously not been reported in animals or humans
58 (1). By press time, the novel coronavirus (SARS-CoV-2) has resulted in a huge
59 epidemic in China and other 88 countries/territories, and there have been 98,129
60 globally confirmed cases of SARS-CoV-2 infection (COVID-19), including 3, 380
61 deaths (World Health Organization, COVID-19 Situation Report-46) (2). As the
62 current outbreak of COVID-19 continues to evolve, COVID-19 has become a serious
63 global health concern because of the possible fatal progression and rapidly growing
64 numbers of new cases (3). Herein, it is urgently necessary to devise as many specific
65 detection assays as possible to provide early, rapid and reliable diagnosis of
66 COVID-19.

67 Diagnosis of COVID-19 based on clinical symptoms, especially in the early
68 stages of this disease, is extremely difficult as there are no characteristic initial
69 manifestations of COVID-19 (4). Although genome sequencing had high accuracy for
70 diagnose of COVID-19, it was not applicable in rapid diagnosis for clinical
71 large-samples because of its longer sequencing time and high requirements for
72 experimental equipment (5). In the current outbreak of COVID-19, real-time reverse
73 transcription polymerase chain reaction (rRT-PCR) was employed to detect
74 SARS-CoV-2 in public health and clinical laboratories because it a specific and
75 sensitive diagnostic method for detection the novel coronavirus (6). However,
76 rRT-PCR technique strongly relies on complex apparatus, skilled personnel and a
77 stable power supply, the total run time of rRT-PCR test is several hours from the
78 clinical specimens to result reporting. In particular, some regions where outbreaks of
79 COVID-19 emerge usually do not provide sufficient infrastructure for good rRT-PCR
80 diagnostic services, especially for field laboratories and resource-limited settings (7).
81 Hence, there is an urgent requirement for easy-to-use, more rapid and simpler
82 detection techniques for diagnosis of COVID-19.

83 Loop-mediated isothermal amplification (LAMP), which is the most popular

84 isothermal amplification assay, is able to offer a diagnostic testing option for this
85 scenario (8). The details of LAMP mechanism have been described by previous
86 publications (9). Using the LAMP-based protocols, nucleic acid amplification is
87 conducted under isothermal conditions (e.g., in a heating block) with high efficiency,
88 specificity and speed, eliminating the use of precision thermal cycler for thermal
89 change (9, 10). The LAMP technique is highly specific, because recognition of target
90 sequence by six or eight independent regions is required (11). Thus far, LAMP
91 combined with reverse transcription assay (RT-LAMP) had been developed for the
92 detection of multiple respiratory RNA viruses (e.g., influenza viruses, middle east
93 respiratory syndrome and severe acute respiratory syndrome coronavirus) (12).
94 Regarding these traits of LAMP technique, development of a LAMP-based assay for
95 diagnosis of COVID-19 can overcome the shortcomings posed by rRT-PCR methods,
96 and facilitates rapid diagnosis and surveillance of COVID-19.

97 Up to now, two informal published LAMP assays have been developed for
98 diagnosis of COVID-19, and preliminarily evaluated using clinical or stimulated
99 respiratory samples (13, 14). Unfortunately, only a genetic sequence (Open reading
100 frame 1a/b; F1ab) was amplified and detected in the two systems, an unreliable
101 diagnosis result may be obtained when the two COVID-19 LAMP assays detected a
102 sample with high homology sequence of SARS-CoV-2 (e.g., bat severe acute
103 respiratory syndrome-like coronavirus, GenBank KY417152.1). Traditional
104 monitoring techniques (e.g., agarose gel electrophoresis, SYBR dyes and PH
105 indicator), which were non-specific for COVID-19 LAMP products, were employed
106 for confirming the two COVID-19 LAMP results. In addition, the electrophoresis is a
107 time-consuming and tedious procedure, and the judgment of color change of reaction
108 vessel by unaided eye is potentially subjective. Therefore, there is a continuous
109 command for devising the new LAMP-based assays, which are capable of
110 simultaneously detecting multiple targets of SARS-CoV-2, providing more rapid and
111 objective result, and facilitating simpler diagnosis.

112 Here, a 'one-step' and 'one-tube' RT-LAMP coupled with nanoparticles-based
113 biosensor (NBS) assay (RT-LAMP-NBS) was developed for diagnosis of COVID-19

114 (**Figure 1 and 2**). Two target sequences, including F1ab and nucleoprotein gene (np),
115 were simultaneously amplified in an isothermal reaction, and detected in a test step.
116 We will expound the basic COVID-19 RT-LAMP principle, optimize the reaction
117 parameters (e.g., amplification temperature), and demonstrate its feasibility.

118

119 **RESULTS**

120 **COVID-19 RT-LAMP-NBS design**

121 In the LAMP system (**Figure 1**), FIP (forward inner primer) initiates the isothermal
122 amplification, and the new strand derived from FIP primer was displaced by the F3
123 (forward primer) synthesis (**Step 1**). Then, 2 primers, including BIP (backward inner
124 prime) and B3 (backward primer), annealed to the newly produced strand (**Step 2**),
125 and displacement enzyme (*Bst* 2.0) extended in tandem generating a dumb-bell form
126 product (**Step 3**). Thus, the stem-loop stem product can server as the template for the
127 second stage of the LAMP reaction (exponential amplification). The LB* primer
128 (backward loop primer), which was labeled with biotin at the 5' end, could anneal to a
129 distinct product derived from the exponential LAMP reaction stage (**Step 4**). The LB*
130 product also severed as the template for next amplification by LF* (forward loop
131 primer), which was modified at the 5' end with hapten (**Step 5**). As a result, a
132 double-labeled detectable product (LF*/LB* product) was formed, and one end of the
133 LF*/LB* product was labeled with hapten, and the other end with biotin (**Step 6, 7**).
134 One hapten is assigned to one primer set, which provide the possibility for multiplex
135 LAMP detection.

136 A representative schematic of COVID-19 RT-LAMP-NBS assay were displayed
137 in **Figure 2**. In the COVID-19 RT-LAMP system, fluorescein (FITC) was assigned to
138 F1ab primer set, and digoxigenin (Dig) for np primer set. Hence, F1ab-LF* and
139 F1ab-LB* primers were labeled at the 5' end with FITC and biotin, and np-LF* and
140 np-LB* for Dig and biotin, respectively (**Figure 2A**). With the assistance of AMV
141 (avian myeloblastosis virus reverse transcriptase), the RNA (SARS-CoV-2 template)
142 was converted to cDNA, which acted as the material for subsequent LAMP
143 amplification (**Figure 2B**). After 40 min at 63°C, F1ab-LAMP products were

144 simultaneously labeled with FITC and biotin, and np-LAMP products for Dig and
145 biotin (**Figure 2C**).

146

147 **The principle of NBS visualization of COVID-19 RT-LAMP results**

148 As shown in the **Figure 3**, the result readout of COVID-19 RT-LAMP assay was
149 exhibited using the NBS. The details of NBS was shown **Figure 3A** (Seen in
150 'Materials and Method' section). For visualization of COVID-19 RT-LAMP results
151 using NBS, aliquots (0.5 μ l) of reaction mixtures were deposited into the sample
152 region (**Figure 3B**, step 1), and an aliquot (80 μ l) running buffer then was deposited
153 on the same region (**Figure 3B**, step 2). At the detection stage, running buffer moves
154 along NBS through capillary action, and rehydrates the SA-DNPS immobilized in the
155 conjugate pad. The end of F1ab-RT-LAMP products labeled with FITC was captured
156 by the anti-FITC antibody located in TL1 region (Test line 1), and the end of
157 np-RT-LAMP products with Dig was captured by anti-Dig antibody located in TL2
158 region (Test line 2). The other ends of F1ab- and np-RT-LAMP products, labeled with
159 biotin, bind streptavidin-conjugated color nanoparticles for visualization (**Figure 3B**,
160 step 3). The excess streptavidin-conjugated color nanoparticles were captured by
161 biotinylated bovine serum albumin immobilized in CL (Control line), which
162 demonstrated the working condition of NBS (**Figure 3B**, step 3). The interpretation of
163 the COVID-19 RT-LAMP results using NBS was shown in **Figure 3C**.

164

165 **Confirmation and detection of F1ab-, np- and COVID-19 RT-LAMP products**

166 The positive vessels of F1ab-, np- and COVID-19 RT-MCDA assay were visualized
167 as light green using VDR (Visual detection reagent), while the reaction tubes of
168 negative and blank controls remained colorlessness (**Figure S1**, top row). Using NBS,
169 TL1 and CL were observed on the detection region for positive F1ab-RT-LAMP
170 results, and TL2 and CL for positive np-RT-LAMP results. TL1, TL2 and CL
171 simultaneously appeared on the detection region of NBS for positive COVID-19
172 RT-LAMP results. Only CL appeared on the analysis area of NBS for negative and
173 blank controls of F1ab-, np- and COVID-19 RT-LAMP results (**Figure S1**, bottom

174 row). These results indicated that F1ab- and np-LAMP primer sets were available for
175 establish the COVID-19 RT-LAMP NBS assay for rapid and reliable detection of
176 SARS-CoV-2. The parameter of optimal temperature for COVID-19 RT-LAMP
177 technique also was tested, and reaction temperature of 63°C was used for performing
178 the COVID-19 RT-LAMP amplification (**Figure S2** and **S3**).

179

180 **Sensitivity of COVID-19 RT-LAMP-NBS assay**

181 The COVID-19 RT-LAMP-NBS was able to detect down 12 copies (each of
182 F1ab-plasmid and np-plasmid) (**Figure 4**). Two target genes were detected and
183 identified in a one-tube reaction (**Figure 4A**). The COVID-19 RT-LAMP results
184 using NBS were in consistent with turbidity and VDR detection (**Figure 4B** and **4C**),
185 while traditional monitoring techniques (VDR and turbidity) could not facilitate
186 multiplex analysis. Furthermore, the sensitivity of COVID-19 RT-LAMP-NBS assay
187 was in conformity with F1ab- and np-RT-LAMP assay (**Figure 4, S4** and **S5**).

188 The optimal duration time of COVID-19 RT-LAMP-NBS assay at the isothermal
189 stage also was determined, and the template level at the detection limit appeared three
190 red lines (TL1, TL2 and CL) when the RT-LAMP reaction was carried out only 30
191 min at 63°C (**Figure S6**). For the RNA template detection, a reverse transcription
192 process (10 min) is essential, thus a COVID-19 RT-LAMP reaction time of 40 min
193 was recommended for detection of clinical samples. Therefore, the whole diagnosis
194 process of COVID-19 RT-LAMP-NBS, including sample collection (3 min), rapid
195 RNA extraction (15 min), RT-LAMP reaction (40 min) and result interpretation (<2
196 min), was finished approximately 1 h (**Figure 5**).

197

198 **Specificity of RT-LAMP-NBS assay**

199 The positive COVID-19 RT-LAMP-NBS results were obtained only from positive
200 controls (120 copies each of F1ab-plasmid and np-plasmid) (**Table S1**). The negative
201 results were observed in all pathogens of non-SARS-CoV-2 (virus, bacteria and fungi),
202 in which only a red band (CL) was observed in the biosensor detection regions,
203 indicating no cross-reaction with non-SARS-CoV-2 templates (**Table S2**).

204 **Application of the RT-LAMP-NBS assay in clinical samples**

205 Of the total of 129 respiratory samples, which were initially analyzed using rRT-PCR
206 in Sanya People's Hospital in 2020, were enrolled in this report. Particularly, only the
207 RNA templates were used after rRT-PCR performance. Among all the enrolled
208 COVID-19 patients (33), the sensitivity of COVID-19 RT-LAMP-NBS assay 100%
209 (33/33). The specificity was 100% (96/96) for COVID-19 RT-LAMP-NBS assay
210 among non-COVID-19 patients, which were diagnosed as having pneumonia with
211 confirmed pathogen in clinical laboratory of SanYa People's Hospital. These
212 preliminary results revealed that the proposed COVID-19 RT-LAMP-BS assay had a
213 high sensitivity and specificity for diagnosis of SARS-CoV-2 infection.

214

215 **Discussion**

216 An ongoing epidemic by SARS-CoV-2, starting in last December 2019 in Wuhan,
217 China, is a huge public health concern (15). As of today (9 March 2020), 98 129 total
218 confirmed cases have been documented, with 80 711 cases in China and the
219 remaining cases distributed other 88 countries/regions in every continent (WHO,
220 COVID-19 Situation Report-46) (16). Hence, there has been an immediate
221 requirement for early, rapid and reliable diagnostic tests in the current outbreak. Such
222 detection techniques are required not only in these countries where SARS-CoV-2
223 infection are spreading but also in countries/regions threatened by SARS-CoV-2
224 infection, even in countries/regions where COVID-19 have not yet been emerged.

225 Here, we reported a novel LAMP-based test for simple, rapid and reliable
226 diagnosis of COVID-19, name COVID-19 RT-LAMP-NBS. Our assay merged
227 LAMP amplification, reverse transcription, multiplex analysis with
228 nanoparticles-based biosensor, and facilitated the diagnosis of COVID-19 in a
229 one-step, single-tube reaction. Only simple apparatus (e.g., a water bath or a heating
230 block) were need to maintain a constant temperature (63°C) for 40 min. Compared
231 with the developed COVID-19 RT-LAMP assays, the RT-LAMP results in this report
232 were visually and objectively indicated by NBS, which was a simple and easy-to-use
233 platform, avoiding the requirement of complex process (e.g., electrophoresis), special

234 reagents (e.g., PH indicator) and expensive instrument (e.g., real-time turbidity) (13,
235 14). Total analysis procedure could be complete approximately 1 h, including sample
236 collection (3 min), rapid RNA extraction (15 min), RT-LAMP reaction (40 min) and
237 result interpretation (< 2 min). Considering these traits, COVID-19 RT-LAMP-NBS
238 assay is a rapid, economical and technically simple method, offering a measure of
239 practicality for field and clinical laboratories, especially for resource-challenged
240 settings.

241 Two RT-LAMP primer sets, including F1ab-RT-LAMP and np-RT-LAMP
242 primer sets, were specifically designed recognizing eight regions of target genes
243 (**Figure 6**), guaranteeing the high specificity for SARS-CoV-2 detection. The data of
244 analytical specificity revealed that no false-positive results were produced from
245 non-SARS-CoV-2 templates, and positive results were obtained from positive control
246 and SARS-CoV-2 templates (**Table S1**). Moreover, two targets (F1ab and np genes)
247 could be simultaneously amplified and detected in a 'one-step' RT-LAMP reaction,
248 which further guaranteed the assay's reliability. Thus, our approach could effectively
249 avoid the undesired results yielded from the developed COVID-19 RT-LAMP assays
250 that only amplified and detected a target gene (e.g., F1ab) (13, 14).

251 The data of analytical sensitivity validated that RT-LAMP-NBS assay is
252 sufficiently sensitive for diagnosis of COVID-19. Us this protocol, detection limit of
253 COVID-19 RT-LAMP-NBS was 12 copies each of F1ab-plasmid and np-plasmid,
254 which is in conformity with assay's sensitivity generated from F1ab-RT-LAMP-NBS
255 and N-RT-LAMP-NBS detection (**Figure 4, S4 and S5**). The COVID-19
256 RT-LAMP-NBS assay did not improve or decrease the analytical sensitivity when
257 compared with the signlex analysis (F1ab-RT-LAMP and np-RT-LAMP assays). In
258 this report, we did not compare the sensitivity results obtained from COVID-19
259 RT-LAMP-NBS with rRT-PCR assay, because the quality of commercially available
260 test kits for SARS-CoV-2 detection remains uneven. These commercial rRT-PCR
261 assays used in Sanya People's Hospital produce uninform results when they were
262 applied to analyze the 10-fold diluted plasmid templates. For detection the RNA
263 templates extracted from respiratory samples, 100% (33/33) of clinical samples

264 examined by rRT-PCR exhibited completely consistent diagnosis, and analytical
265 specificity was also 100% (96/96) for COVID-19 RT-LAMP-NBS when analyzing
266 the RNA templates from non-SARS-CoV-2 infection patients.

267

268 **Conclusion**

269 The one-step single-tube COVID-19 RT-LAMP-NBS assay devised in this report
270 offers an attractive diagnosis tool for SARS-CoV-2 detection. The nearly
271 equipment-free platform of COVID-19 RT-LAMP-NBS makes it applicable for
272 resource-limited laboratories (e.g., field laboratories), and the diagnosis results are
273 easy to interpret. The high specificity, sensitivity and feasibility of COVID-19
274 RT-LAMP-NBS assay for detection of SARS-CoV-2, and its low cost and ease of use
275 make the target assay a valuable diagnosis tool for use in field, clinic, public health
276 and primary care laboratories, especially for resource-poor regions.

277

278 **Materials and Methods**

279 **Construction of nanoparticles-based biosensor (NBS)**

280 As shown in **Figure 3A**, NBS contains four components (a sample pad, a conjugate
281 pad, a nitrocellulose membrane and an absorbent pad) (Jie-Yi Biotechnology). Rabbit
282 anti-fluorescein antibody (anti-FITC, 0.2 mg/ml, Abcam. Co., Ltd.), sheep
283 anti-digoxigenin antibody (Anti-Dig, 0.25 mg/mL, Abcam. Co., Ltd.) and biotinylated
284 bovine serum albumin (biotin-BSA, 4 mg/mL, Abcam. Co., Ltd.) were immobilized at
285 detection regions (nitrocellulose membrane, NC) as the test line 1 (TL1), test line 2
286 (TL2) and control line (CL), respectively, with each line separated by 5 mm. Dye
287 streptavidin coated polymer nanoparticles (SA-DNPs, 129 nm, 10mg mL⁻¹, 100mM
288 borate, pH 8.5 with 0.1% BSA, 0.05% Tween 20 and 10mM EDTA) were
289 immobilized at the conjugated regions. Thus, the NBS devised here can detect three
290 targets (a chromatography control and two target amplicons). The assembled NBS
291 were cut into 4-mm dipsticks, and dryly stored at the room temperature until use.

292

293 **Primer design**

294 Two RT-LAMP primer sets (F1ab-RT-LAMP and np-RT-LAMP) were designed
295 according the LAMP mechanism using a specialized software (PrimerExplore V5),
296 which targeted F1ab and np gene of SARS-CoV-2 (GenBank MN908947,
297 Wuhan-Hu-1) (**Figure 6**). Then, a Blast analysis of the GenBank nucleotide database
298 was performed for the F1ab- and np-LAMP primers to validate sequence specificity.
299 The more details of primer design, locations, sequences and modifications were
300 shown in **Figure 6** and **Table S2**. All of the oligomers were synthesized and purified
301 by RuiBo Biotech. Co., Ltd. (Beijing, China) at HPLC purification grade.

302

303 **Reverse transcription LAMP reaction (RT-LAMP)**

304 The conventional RT-LAMP (F1ab- and np-RT-LAMP) was carried out in a one-step
305 reaction in a 25- μ l mixture containing 12.5 μ l 2 \times isothermal reaction buffer [40 mM
306 Tris-HCl (pH 8.8), 40 mM KCl, 16 mM MgSO₄, 20 mM (NH₄)₂SO₄, 2 M betaine and
307 0.2 % Tween-20], 8 U of Bst 2.0 DNA polymerase (New England Biolabs), 5 U of the
308 avian myeloblastosis virus reverse transcriptase (Invitrogen), 1.4 mM dATP, 1.4 mM
309 dCTP, 1.4 mM dGTP, 1.4 mM dTTP, 0.4 μ M each of F3 and B3, 0.4 μ M each of LF,
310 LF*, LB and LB*, 1.6 μ M each of FIP and BIP and template (1 μ l for the standard
311 plasmid).

312 The COVID-19 RT-LAMP was also performed in a one-step reaction in a 25- μ l
313 mixture containing 12.5 μ l 2 \times isothermal reaction buffer [40 mM Tris-HCl (pH 8.8),
314 40 mM KCl, 16 mM MgSO₄, 20 mM (NH₄)₂SO₄, 2 M betaine and 0.2 % Tween-20],
315 8 U of Bst 2.0 DNA polymerase (New England Biolabs), 5 U of the avian
316 myeloblastosis virus reverse transcriptase (Invitrogen), 1.4 mM dATP, 1.4 mM dCTP,
317 1.4 mM dGTP, 1.4 mM dTTP, 0.25 μ M each of F1ab-F3 and F1ab-B3, 0.25 μ M each
318 of F1ab-LF, F1ab-LF*, F1ab-LB and F1ab-LB*, 1.0 μ M each of F1ab-FIP and
319 F1ab-BIP, 0.15 μ M each of np-F3 and np-B3, 0.15 μ M each of np-LF, np-LF*, np-LB
320 and np-LB*, 0.6 μ M each of np-FIP and np-BIP and template (1 μ l for the each
321 standard plasmid, 5 μ l for samples).

322 The monitoring techniques, including real-time turbidity (LA-320C), visual
323 detection reagents (VDR) and NBS, were employed for confirming the RT-LAMP

324 reactions and optimizing the reaction parameters (e.g., reaction temperature and
325 isothermal time).

326

327 **Sensitivity of the RT-LAMP-NBS assay**

328 Two standard plasmids (F1ab-plasmid and np-plasmid) were commercially
329 constructed by Tianyi-Huiyuan Biotech. Co., Ltd. (Beijing, China), which contain the
330 F1ab and np sequences, respectively. Ten-fold serial dilutions (1.2×10^4 to 1.2×10^{-2}
331 copies) of F1ab-plasmid and np-plasmid were used to evaluate assay's sensitivity. The
332 plasmid concentration at detection limit level was employed for testing the duration
333 time required by COVID-19 RT-LAMP-NBS assay.

334

335 **Specificity of the COVID-19 RT-LAMP-NBS assay**

336 The specificity of the COVID-19 RT-LAMP-NBS assay was examined by detecting
337 the templates extracted from various pathogens, including viruses, bacteria and fungi
338 (**Table S1**).

339

340 **Feasibility of COVID-19 RT-LAMP-NBS using clinical samples**

341 Respiratory samples were collected from COVID-19 infection patients in SanYa
342 People's Hospital, Hainan, which were defined according to standard diagnosis and
343 treatment criteria of COVID-19 (Trial Version 6). The RNA templates extracted from
344 respiratory samples were used after clinical and laboratory diagnosis, which was
345 conducted using the RT-qPCR kit (Recommended by the China CDC). Collection of
346 these RNA templates and analysis of them were approved by SanYa People's Hospital.
347 5 μ l RNA was used as templates for performing the COVID-19 RT-LAMP-NBS test.

348

349 **Contributors:** Yi Wang and Xiong Zhu conceived and designed this study. Xiong Zhu, Xiaoxia
350 Wang, Licheng Wang, Limei Han, Huan Li, Ting Chen, Shaojin Chen, Mei Xing, Hai Chen and Yi
351 Wang performed the experiments. Xiaoxia Wang, Xiong Zhu and Yi Wang analyze the data. Xiong
352 Zhu, Xiaoxia Wang and Yi Wang contributed the reagents and analysis tools. Xiong Zhu, Xiaoxia
353 Wang, Licheng Wang, Limei Han, Huan Li, Ting Chen, Shaojin Chen, Mei Xing and Hai Chen
354 contributed the materials. Yi Wang conducted the software. Xiong Zhu and Xiaoxia Wang drafted the
355 manuscript. Xiong Zhu and Yi Wang revised the manuscript.

356 **Funding:** This work was supported by grants from the Key Research and Development Program of
357 Hainan Province (ZDYF2019149, ZDYF2017163), and Youth Science Foundation of Natural Science
358 Fund of Hainan Province (818QN326).

359 **Competing interests:** The authors declare that they have no competing interests.

360 **Ethical approval:** This study was approved by the Ethics Committee of the Sanya People's Hospital
361 (SYPH-2019(41)-2020-03-06).

362 **Data sharing:** No additional data available.

363 **Transparency declaration:** The lead author and guarantor affirms that the manuscript is an honest,
364 accurate, and transparent account of the study being reported; that no important aspects of the study
365 have been omitted; and that any discrepancies from the study as planned and registered have been
366 explained.

367

368 Reference

- 369 1. X.-W. Xu *et al.*, Clinical findings in a group of patients infected with the 2019 novel
370 coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. *Bmj*
371 **368**, (2020).
- 372 2. R. Lu *et al.*, Genomic characterisation and epidemiology of 2019 novel coronavirus:
373 implications for virus origins and receptor binding. *The Lancet* **395**, 565 (2020).
- 374 3. C. Wang, P. W. Horby, F. G. Hayden, G. F. Gao, A novel coronavirus outbreak of
375 global health concern. *The Lancet* **395**, 470 (2020).
- 376 4. C. Huang *et al.*, Clinical features of patients infected with 2019 novel coronavirus in
377 Wuhan, China. *The Lancet* **395**, 497 (2020).
- 378 5. F. Wu *et al.*, A new coronavirus associated with human respiratory disease in China.
379 *Nature*, 1 (2020).
- 380 6. V. M. Corman *et al.*, Detection of 2019 novel coronavirus (2019-nCoV) by real-time
381 RT-PCR. *Eurosurveillance* **25**, (2020).
- 382 7. D. K. Chu *et al.*, Molecular diagnosis of a novel coronavirus (2019-nCoV) causing an
383 outbreak of pneumonia. *Clinical chemistry*, (2020).
- 384 8. Y. Wang *et al.*, Loop-mediated isothermal amplification label-based gold nanoparticles
385 lateral flow biosensor for detection of *Enterococcus faecalis* and *Staphylococcus*
386 *aureus*. *Frontiers in microbiology* **8**, 192 (2017).
- 387 9. G. A. Obande, K. K. B. Singh, Current and Future Perspectives on Isothermal Nucleic
388 Acid Amplification Technologies for Diagnosing Infections. *Infection and Drug*
389 *Resistance* **13**, 455 (2020).
- 390 10. N. G. Schoepp *et al.*, Rapid pathogen-specific phenotypic antibiotic susceptibility
391 testing using digital LAMP quantification in clinical samples. *Science Translational*
392 *Medicine* **9**, eaal3693 (2017).
- 393 11. N. Chotiwan *et al.*, Rapid and specific detection of Asian-and African-lineage Zika
394 viruses. *Science translational medicine* **9**, eaag0538 (2017).
- 395 12. Y. P. Wong, S. Othman, Y. L. Lau, S. Radu, H. Y. Chee, Loop-mediated isothermal
396 amplification (LAMP): a versatile technique for detection of micro-organisms. *Journal*
397 *of applied microbiology* **124**, 626 (2018).
- 398 13. L. E. Lamb, S. N. Bartolone, E. Ward, M. B. Chancellor, Rapid Detection of Novel
399 Coronavirus (COVID19) by Reverse Transcription-Loop-Mediated Isothermal
400 Amplification. *Available at SSRN 3539654*, (2020).
- 401 14. L. Yu *et al.*, Rapid colorimetric detection of COVID-19 coronavirus using a reverse
402 tran-scriptional loop-mediated isothermal amplification (RT-LAMP) diagnostic
403 plat-form: iLACO. *medRxiv*, (2020).
- 404 15. D. L. Heymann, N. Shindo, COVID-19: what is next for public health? *The Lancet*,
405 (2020).
- 406 16. Q. Liu *et al.*, Assessing the Tendency of 2019-nCoV (COVID-19) Outbreak in China.
407 *medRxiv*, (2020).

408

409

410 **Figure legends**

411

412





Figure 1. Outline of LAMP assay

Top row, outline of LAMP with LF* and LB*; **Bottom row**, schematic depiction of the new forward/backward loop primer (LF*/LB*). LF* was labeled with hapten at the 5' end, and LB* was labeled with biotin at the 5' end.

418

419



420

421

Figure 2. Mechanistic description of the COVID-19 RT-LAMP-NBS assay

422

(A), Preparing the amplification mixtures. (B), RT-LAMP reaction. (C), The

423

detectable COVID-19 RT-LAMP products were formed. F1ab-RT-LAMP products

424


were simultaneously labeled with FITC and biotin, and np-RT-LAMP labeled with

425

Dig and biotin.

426

427




428

429 **Figure 3. The principle of NBS for visualization of COVID-19 RT-LAMP**
430 **products**

431 (A), The details of NBS. (B), The principle of NBS for COVID-19 RT-LAMP
432 products. (C), Interpretation of the COVID-19 RT-LAMP results. I, a positive result for F1ab and np (TL1, TL2 and CL appear on the NBS); II, a positive result for N
433 (TL2 and CL appear on the detection region); III, a positive result for F1ab (TL1 and
434 CL appear on the detection region); IV, negative (only the control line appears on the
435 NBS).
436

437

438



439

440

Figure 4. Sensitivity of COVID-19 RT-LAMP-NBS assay

441 **A**, NBS applied for reporting the results; **B**, Real-time turbidity applied for reporting

442 the results; **C**, VDR applied for reporting the results. NBS (**A**)/Signals (**B**)/Tubes (**C**)

443 1-8 represented the plasmid levels (each of F1ab-plasmid and np-plasmid) of 1.2×10^4 ,

444 1.2×10^3 , 1.2×10^2 , 1.2×10^1 , 1.2×10^0 , 1.2×10^{-1} , 1.2×10^{-2} copies per reaction and blank

445 control (DW). The plasmid levels of 1.2×10^4 to 1.2×10^1 copies per reaction produced

446 the positive reactions.

447

448



449

450

Figure 5. The workflow of COVID-19 RT-LAMP-BS assay

451

Four steps, including sample collection (3 min), rapid RNA extraction (15 min),

452

RT-LAMP reaction (40 min) and result reporting (< 2 min), were required for conduct

453


the COVID-19 RT-LAMP-NBS diagnosis test, and the whole process could be

454

completed approximately 60 min.

455

456



457

458

Figure 6. Primer design of COVID-19 RT-MCDA-BS assay

459

Up row, SARS-CoV-2 genome organization (GenBank: MN908947, Wuhan-Hu-1).

460

The length of all genes was not displayed in scale. **Bottom row**, nucleotide sequence

461

and location of F1ab and np gene used to design COVID-19 RT-LAMP primers. Part

462

of nucleotide sequences of F1ab (**Left**) and N (**Right**) are listed. The sites of primer

463

sequence were underline. Right arrows and Left arrows showed the sense and

464

complementary sequence that are used.

465

* Note: F1ab (Open reading frame 1a/b); S (Spike protein); E (Envelope protein); M

466

(Membrane protein); N (Nucleoprotein); Accessory proteins (3, 6, 7a, 7b, and 9b).